Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study

Abstract

Background

Aspirin is widely used as a cardioprotective agent due to its antiplatelet and anti-inflammatory properties. The literature has assessed and evaluated its role in hospitalized COVID-19 patients. However, no data are available regarding its role in COVID-19 critically ill patients. This study aimed to evaluate the use of low-dose aspirin (81-100 mg) and its impact on outcomes in critically ill patients with COVID-19.

Method

A multicenter, retrospective cohort study of all critically ill adult patients with confirmed COVID-19 admitted to intensive care units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classified into two groups based on aspirin use during ICU stay. The primary outcome was in-hospital mortality, and other outcomes were considered secondary. Propensity score matching was used (1:1 ratio) based on the selected criteria.

Results

A total of 1033 patients were eligible, and 352 patients were included after propensity score matching. The in-hospital mortality (HR 0.73 [0.56, 0.97], p = 0.03) was lower in patients who received aspirin during stay. Conversely, patients who received aspirin had a higher odds of major bleeding than those in the control group (OR 2.92 [0.91, 9.36], p = 0.07); however, this was not statistically significant. Additionally, subgroup analysis showed a possible mortality benefit for patients who used aspirin therapy prior to hospitalization and continued during ICU stay (HR 0.72 [0.52, 1.01], p = 0.05), but not with the new initiation of aspirin (HR 1.22 [0.68, 2.20], p = 0.50).

Conclusion

Continuation of aspirin therapy during ICU stay in critically ill patients with COVID-19 who were receiving it prior to ICU admission may have a mortality benefit; nevertheless, it may be associated with an increased risk of significant bleeding. Appropriate evaluation for safety versus benefits of utilizing aspirin therapy during ICU stay in COVID19 critically ill patients is highly recommended.

Keywords

COVID-19 SARS-coV-2 aspirin critically ill intensive care units (ICUs)30-day mortality in-hospital mortality

Get full access to this article

View all access options for this article.

References

McGoogan

. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239‐1242. doi:10.1001/jama.2020.2648

Ahmed HA

Merrell

Ismail

, et al. Rationales and uncertainties for aspirin use in COVID-19: a narrative review. Fam Med Commun Health. 2021;9(2):e000741. doi:10.1136/fmch-2020-000741

Saleh

Hafiz

Alsulaiman

, et al. Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): a multicenter cohort study. Am Heart J Plus. 2021;7:100033. doi:10.1016/j.ahjo.2021.100033.

Zhang

Cao

Jiang

, et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020;50(3):580‐586. doi:10.1007/s11239-020-02182-9

Chernysh

Nagaswami

Kosolapova

, et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep. 2020;10(1):5112. Published 2020 Mar 20. doi:10.1038/s41598-020-59526-x.

Klok

Kruip

MJHA

van der Meer

NJM

, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148‐150. doi:10.1016/j.thromres.2020.04.041

INSPIRATION Investigators , et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620‐1630. doi:10.1001/jama.2021.4152

REMAP-CAP Investigators , et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med. 2021;385(9):777‐789. doi:10.1056/NEJMoa2103417

Zhou

. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205‐1208. doi:10.1007/s00277-020-04019-0

10.

Hottz

Azevedo-Quintanilha

Palhinha

, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136(11):1330‐1341. doi:10.1182/blood.2020007252

11.

Meizlish

Goshua

Liu

, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021;96(4):471‐479. doi:10.1002/ajh.26102

12.

Chow

Khanna

Kethireddy

, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021;132(4):930‐941. doi:10.1213/ANE.0000000000005292

13.

Osborne

Veigulis

Arreola

Mahajan

Röösli

Curtin

. Association of mortality and aspirin prescription for COVID-19 patients at the veterans health administration. PLoS One. 2021;16(2):e0246825. Published 2021 Feb 11. doi:10.1371/journal.pone.0246825.

14.

COVID19. Ministry of Health (MOH). https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Pages/covid19.aspx. Published 2021. Accessed February 22, 2022.

15.

Schulman

Kearon

; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692‐694. doi:10.1111/j.1538-7836.2005.01204.x

16.

Lin

Chen

. Acute kidney injury classification: AKIN and RIFLE criteria in critical patients. World J Crit Care Med. 2012;1(2):40‐45. Published 2012 Apr 4. doi:10.5492/wjccm.v1.i2.40.

17.

Rodriguez-Roisin

. Pulmonary gas exchange in acute respiratory failure. Eur J Anaesthesiol. 1994;11(1):5‐13.

18.

Aghajani M

Moradi

Amini

, et al. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. J Med Virol. 2021;93(9):5390‐5395. doi:10.1002/jmv.27053

19.

Sahai

Bhandari

Koupenova

, et al. SARS-CoV-2 receptors are expressed on human platelets and the effect of aspirin on clinical outcomes in COVID-19 patients. Preprint. Res Sq. 2020:rs.3.rs-119031. Published 2020 Dec 23. doi:10.21203/rs.3.rs-119031/v1.

20.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637‐1645. doi:10.1016/S0140-6736(21)00676-0

21.

Yuan

Chen

Wang

. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 2021;25(2):1263‐1273. doi:10.1111/jcmm.16198

22.

Alegbeleye

Akpoveso

O-OP

Alegbeleye

Mohammed

Esteban-Zubero

. The novel aspirin as breakthrough drug for COVID-19: a narrative review. Iberoam J Mede. 2020;2(4):335‐350. https://doi.org/10.53986/ibjm.2020.0058

23.

Zheng

Roddick

. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis [published correction appears in JAMA. 2019 Jun 11;321(22):2245]. JAMA. 2019;321(3):277‐287. doi:10.1001/jama.2018.20578

24.

McNeil

Wolfe

Woods

, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509-1518. doi:10.1056/NEJMoa1805819

25.

De Berardis

Lucisano

D'Ettorre

, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307(21):2286‐2294. doi:10.1001/jama.2012.5034

26.

Cook

Fuller

Guyatt

, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330(6):377‐381. doi:10.1056/NEJM199402103300601

27.

Lauzier

Arnold

Rabbat

, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med. 2013;39(12):2135‐2143. doi:10.1007/s00134-013-3044-3

28.

Hayakawa

. Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments. Open Access Emerg Med. 2017;10:25‐29. Published 2017 Dec 28. doi:10.2147/OAEM.S135909

29.

NCT04365309. Protective Effect of Aspirin on COVID-19 Patients [Internet]. https://clinicaltrials.gov/show/NCT04365309. 2020 [cited 2021 Sep 3]. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103526/full.